RPG Life Sciences is currently trading at Rs. 270.90, up by 37.85 points or 16.24% from its previous closing of Rs. 233.05 on the BSE.
The scrip opened at Rs. 233.00 and has touched a high and low of Rs. 272.50 and Rs. 230.00 respectively. So far 223346 shares were traded on the counter.
The BSE group 'B ' stock of face value Rs. 8 has touched a 52 week high of Rs. 360.60 on 03-Dec-2015 and a 52 week low of Rs. 138.00 on 24-Aug-2015.
Last one week high and low of the scrip stood at Rs. 246.85 and Rs. 221.90 respectively. The current market cap of the company is Rs. 409.85 crore.
The promoters holding in the company stood at 66.79%, while Institutions and Non-Institutions held 0.29% and 32.92% respectively.
RPG Life Sciences has entered into a technical alliance with Italian cosmetic leader Labo Cosprophar. The company is in-licensing two research-based products to be launched in the Indian cosmetic market this July. Moreover, a separate division has been created to market these unique products titled Crescina and Fillerina, specializing in hair-fall control and anti-aging, respectively.
Crescina is a research-based global product designed for hair-regrowth with nine patents worldwide. It is a blend of specialized actives which work to activate hair follicle stem cells that results in development of new hair and essential peptides and hydrolyzed ingredients provide strength to hair. Fillerina is another breakthrough product designed for anti-aging treatment with Swiss patent. Fillerina is the first dermo-cosmetic filler for external use.
RPG Life Sciences is an integrated pharmaceutical company operating in the domestic and international markets in the Branded Formulations, Global Generics, Synthetic and Fermentation APIs space. The company is a research based, pharmaceutical company, producing a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1797.80 |
| Dr. Reddys Lab | 1213.90 |
| Cipla | 1486.30 |
| Lupin | 2069.95 |
| Zydus Lifesciences | 948.70 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
Become a savvy and confident
stock investor.
Don't miss out! First 10 users today get it FREE
Download APP
